Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). - Wikidata - wikimedia - TriplyDB

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

http://www.wikidata.org/entity/Q37585155

about

Resistant mechanisms to BRAF inhibitors in melanoma MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Pathways and therapeutic targets in melanoma Beyond BRAF: where next for melanoma therapy?Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Resistance to Raf inhibition in cancer.Understanding the biology of melanoma and therapeutic implications Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma Genotyping of cutaneous melanoma.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma PTEN: Multiple Functions in Human Malignant Tumors Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.Resistance to RAF inhibitors revisited.The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.Braf V600E mutation in melanoma: translational current scenario.Cell Cycle Regulation and Melanoma.The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Contemporary and potential future molecular diagnosis of melanoma.Targeted agents and immunotherapies: optimizing outcomes in melanoma.Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.Converting biology into clinical benefit: lessons learned from BRAF inhibitors.Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.

P2860

Q26739717-45547032-BF60-4A13-96C6-4BD8DC18AD5C Q26771192-2C25CBA9-B025-4418-ADE3-81CB96FF9DC4 Q26799864-A0A408F0-1FB0-4E58-860F-04ED99BD0180 Q26853261-7058780D-67F0-4E89-8486-463229B91E69 Q26865736-B64D3734-0187-4441-BCF2-1BE3B4638B3E Q27006853-59C51D74-73AF-49E5-BE28-0AC6F63395C0 Q27852827-94184822-C9A3-47E5-BAE7-0FF750553F79 Q27853202-347EA96B-008E-48E4-B7D3-2744F1D6A1C6 Q33651779-41AE3B2D-87DD-4DEC-9ED6-2221B331D430 Q33978378-3325F91A-6948-41C3-B5C5-1E5E87D56A1B Q34438555-37B27C1A-2666-487E-852C-170A954C927F Q34662717-06F98CC8-187B-4D45-902F-8F93FACBE645 Q34667738-9BC58CDC-CF48-4B1D-A852-99CB7DC5B3DC Q34667825-05CE6F9E-E90B-45A3-B0D5-25300112EAEA Q34671658-B472345A-DF12-44C4-A91E-74F7F51A825B Q34786402-53246EA5-4101-4B9B-8F3E-0A6BBF37CADE Q34898560-49B91B1D-D1C7-4388-B557-B421AA3D2086 Q35087328-25F78A34-5348-4590-AD2D-DB6DFBFC50BA Q35746524-AE2B0767-EEEC-4846-8686-65DA4253999F Q35810176-3F3AE501-2D46-4125-B935-9FF1ADDE6DBE Q35820476-BEBCFD2F-C690-4A48-BD1E-EBE0D5D4BD3B Q35859282-AAFEFE9C-32E1-42F7-82AF-4887D225D02E Q36194822-08ACDEB0-2D89-409E-9F04-342F630F853A Q36289114-AC65561A-066D-4BBB-8622-C4BD39DA72D7 Q36373537-E8F7C224-C2D9-477E-846D-00324E00B603 Q37625751-73ED2760-7BA2-4C62-81B1-1396E716EFF1 Q37626102-522F0BA3-AEF9-4D2A-9CD1-3909ACAE3352 Q37736532-414D9351-EC9C-47B1-A1AF-7D4A0D16D7E9 Q38148747-1CB25224-076B-49E5-B230-F71B0B35D8A9 Q38238524-BE4CFEF2-B370-4751-BA61-A6047F830CD5 Q38716283-6B5EF50C-56E2-4E4B-A557-31A5A0E15F1E Q38815527-ACC9277A-C10A-419F-8300-03F293A59006 Q38843111-592E1CDA-23A3-4311-9BEB-E95F701E829C Q38847989-38CA5CC3-877B-43F3-841A-8BC3110B7E7F Q38856722-01D6D991-E1B6-4901-BF34-7244672041FA Q38860973-CEFD8555-62FD-4C71-8687-9B40DFD4DC8E Q38870282-16577911-C4D8-4904-9801-E021BD21F47F Q38940098-4A95C956-5E40-4DF8-BD26-8D98097FA318 Q38950577-16292551-8E23-4D4F-B39E-555C2D9A5865 Q39107981-2800EECC-0468-46B4-8D22-41698B8C3C42

P2860

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

http://www.wikidata.org/entity/Q37585155

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tumor genetic analyses of pati ...... bitor dabrafenib (GSK2118436).

@en

Tumor genetic analyses of pati ...... the BRAF inhibitor dabrafenib

@nl

type

label

Tumor genetic analyses of pati ...... bitor dabrafenib (GSK2118436).

@en

Tumor genetic analyses of pati ...... the BRAF inhibitor dabrafenib

@nl

prefLabel

Tumor genetic analyses of pati ...... bitor dabrafenib (GSK2118436).

@en

Tumor genetic analyses of pati ...... the BRAF inhibitor dabrafenib

@nl

P1433

Q37585155-793AAE7D-6D5C-4C82-8DCA-AA9616D004FE

P1476

Q37585155-0AF049D0-5A61-48BD-83DB-A834134DBFE1

P2093

Q37585155-053F59BC-2761-4B0E-8211-BDDD80217434

Q37585155-0BA7977E-C763-4838-A65E-20D8C59ECBEB

Q37585155-18022679-F6A1-4104-B220-8A6CD37ED05A

Q37585155-28BDC9CA-D8C8-4B90-AAFA-FED733E4F9E5

Q37585155-323C68EA-9E03-46D6-9F41-1FFD1E8A7FAC

Q37585155-35F888C3-E8C2-44E8-94A9-86796B978A78

Q37585155-37CAEEDA-6960-4B8F-B9A9-2B001DE37766

Q37585155-89B3D769-CDE7-4C3A-9E93-760A05CC74E6

Q37585155-8EA88A0F-9C5E-4CDD-B486-8DC4D3681B9E

Q37585155-A0B206AB-8052-43B7-9C64-0F5746E780DD

P2860

Q37585155-1E353C44-C430-4E6A-9A99-6830E4F17F88

Q37585155-24D093D1-DED9-4CC0-83E9-AC0B3050D56F

Q37585155-2629B5A5-1D49-4674-94F1-FD57FA6226BA

Q37585155-3329FC9C-C139-46AF-8B27-33F5AA38FD14

Q37585155-4454B785-A6B5-439D-9122-BA15D5705DC6

Q37585155-498E4A71-2AEE-497C-BE19-CF7004BB1D3C

Q37585155-4B529F6A-CF3B-44C9-8541-8F59D058C5B1

Q37585155-4D807C9C-1A11-42CE-98BA-B33B0C768601

Q37585155-4F2921AF-4917-4F98-B036-CD754D2349E5

Q37585155-55506E25-8E3B-4D2A-A0B1-634E704CB507

P304

Q37585155-665056F0-3D22-4B91-AD57-6C203154E6E6

P31

Q37585155-7958C115-EAAF-4409-824B-ED4A9E97535E

P356

Q37585155-71AB6035-45A8-4EAE-84CB-661D83C99475

P407

Q37585155-4F8CA26F-45DF-441D-8E0A-07F141AC0829

P433

Q37585155-A92706C6-9469-4888-B4A7-0EBA9F752C39

P478

Q37585155-3E51E6EF-56C4-4015-93A3-05CD94DBE7F4

P50

Q37585155-3166D52C-2837-41BF-B564-5BBDC5C09E94

Q37585155-50AAC24D-1F1B-48E9-823A-0506C04ACC0A

Q37585155-5A3E77C0-53EB-47C5-8C6D-CC74BE445ED4

Q37585155-AE07E476-8F0F-4C9F-AE82-1065352CA9A4

P577

Q37585155-A0377D77-DEE5-43CD-8313-1903FF126CA9

P698

Q37585155-25F763B8-CBCA-490E-B5B9-9ECF97DD7F91

P921

Q37585155-0872E7F5-D9B3-42CE-B76C-9B7DE0474FBB

Q37585155-7407CDFA-8364-4741-A8CB-747ACB3D58CD

P932

Q37585155-A5270D7B-48DE-4BAE-AE24-D0841393D8F6

P356

1078-0432.CCR-13-0827

P1433

Clinical Cancer Research

P1476

Tumor genetic analyses of pati ...... ibitor dabrafenib (GSK2118436)

@en

P2093

Anna Pavlick

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Martin

http://www.w3.org/2001/XMLSchema#string

Bo Ma

http://www.w3.org/2001/XMLSchema#string

Bradley Wubbenhorst

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Hendrik-Tobias Arkenau

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Infante

http://www.w3.org/2001/XMLSchema#string

Joel Greshock

http://www.w3.org/2001/XMLSchema#string

Kurt D'Andrea

http://www.w3.org/2001/XMLSchema#string

Martin Curtis

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

A landscape of driver mutations in melanoma

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

The genomic complexity of primary human prostate cancer

A comprehensive catalogue of somatic mutations from a human cancer genome

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Melanoma: from mutations to medicine

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

P304

4868-4878

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0827

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Katherine L Nathanson

Michael P. Brown

Georgina V. Long

Richard F. Kefford

P577

2013-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23833299

http://www.w3.org/2001/XMLSchema#string

P921

P932

3924894

http://www.w3.org/2001/XMLSchema#string